RBCC’s Pending JV Partner Amarantus Licenses Alzheimer’s Blood Test Breakthrough

  RBCC’s Pending JV Partner Amarantus Licenses Alzheimer’s Blood Test

Business Wire

NOKOMIS, Fla. -- December 19, 2012

Rainbow Coral Corp.’s (OTCBB: RBCC) pending joint venture partner Amarantus
BioScience, Inc. (OTCBB: AMBS) announced last week that it has licensed a
highly promising new diagnostic known as the LymPro Alzheimer's Disease
Diagnostic Blood Test (LymPro) from Memory Dx, LLC (MDx).

LymPro works by identifying immune-based biomarkers in the blood of patients
suffering from Alzheimer’s, thereby diagnosing the disease and allowing
physicians to definitively differentiate from other forms of dementia,
reducing the need for much costlier brain scans.

The diagnostic has the potential to become an invaluable new tool in
Alzheimer's clinical trials, where there has been a well-documented history of
patient recruitment errors related to inaccurate diagnosis of the disease.

LymPro has received over $3 million in research grants from the National
Institutes of Health (NIH) and completed two phase one clinical studies in
over 80 patients, showing 98% sensitivity and 96% specificity for Alzheimer's
disease diagnosis. Now the diagnostic is ready to move into a phase two
validation study. If successful, LymPro can begin generating revenue as a
laboratory developed test ("LDT") within 18 months of study initiation through
commercial sales and through sales to companies performing Alzheimer's disease
clinical research.

"LymPro has undeniable clinical and commercial potential as a diagnostic blood
test for Alzheimer's disease, and this license strengthens Amarantus’
diagnostic pipeline considerably," said RBCC CEO Patrick Brown. "We are
continuing to discuss partnership opportunities with Amarantus and look
forward to collaborating further in 2013."

The partnership will focus on the development and marketing of the diagnostic
to a clinical population hungry for effective new tests and treatments for
neurological diseases.

For more information on Rainbow BioSciences’ neurological treatment
initiatives, please visitwww.rainbowbiosciences.com/investors.html.

RainbowBioSciences is dedicated to developing new medical and research
technology innovations to compete alongside companies such as Amgen Inc.
(NASDAQ:AMGN),Cell Therapeutics, Inc. (NASDAQ:CTIC) and Abbott Laboratories

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp.
(OTCBB:RBCC). The company continually seeks out new partnerships with
biotechnology developers to deliver profitable new medical technologies and
innovations. For more information on our growth-oriented business initiatives,
please visit our website at [www.RainbowBioSciences.com]. For investment
information and performance data on the company, please

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: This news release contains forward-looking information within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, including statements
that include the words "believes," "expects," "anticipate" or similar
expressions. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, performance
or achievements of the company to differ materially from those expressed or
implied by such forward-looking statements. In addition, description of
anyone's past success, either financial or strategic, is no guarantee of
future success. This news release speaks as of the date first set forth above
and the company assumes no responsibility to update the information included
herein for events occurring after the date hereof.


Rainbow Coral Corp.
Patrick Brown, 813-367-9511
President and CEO
Press spacebar to pause and continue. Press esc to stop.